News

HIV drug under review as firm withdraws FDA application

BMJ 2002; 324 doi: https://doi.org/10.1136/bmj.324.7341.807/a (Published 06 April 2002) Cite this as: BMJ 2002;324:807
  1. Pat Sidley
  1. Johannesburg

    South Africa's already confused and controversial policy on HIV and AIDS was plunged into further disagreement last week as the German pharmaceutical manufacturer Boehringer Ingelheim announced that it would withdraw its application to the US Food and Drug Administration for its antiretroviral drug nevirapine to be registered in the United States for use in preventing HIV transmission from mother to child.

    The drug has been registered for use in adults and children with HIV and AIDS, but in South Africa it has received registration only for use in reducing the risk of HIV transmission from mother to child. Now South Africa's drug …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe